What is AllerQuest?
AllerQuest, LLC is dedicated to developing and providing high-quality skin test reagents for the accurate identification of individuals at risk for penicillin allergies. Its flagship product, PRE-PEN, an FDA-approved diagnostic skin test, has been acquired by ALK-Abelló, which will now handle its manufacturing and distribution. This strategic move allows AllerQuest to focus on advancing allergy testing methodologies while ensuring its key product reaches a wider patient population. The company's expertise spans science, medicine, and pharmaceutical manufacturing, positioning it as a key player in the specialized field of allergy diagnostics.
How much funding has AllerQuest raised?
AllerQuest has raised a total of $399K across 2 funding rounds:
Debt
$150K
Debt
$249K
Debt (2020): $150K with participation from PPP
Debt (2021): $249K led by PPP
Key Investors in AllerQuest
PPP
Public-Private Partnership
PPP
Public-Private Partnership
What's next for AllerQuest?
With the recent acquisition of its core product, PRE-PEN, by ALK-Abelló, AllerQuest is poised for a new phase of strategic development. The substantial capital raised, including the recent major strategic investment, suggests a focus on expanding its research and development capabilities or exploring new diagnostic avenues within the allergy and immunology space. The company's late-stage funding context implies a trajectory towards significant market impact, potentially through further product innovation or strategic partnerships that leverage its established expertise in allergy testing.
See full AllerQuest company page
